Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | IGF1R | P08069 | 1/20 | 0.78 |
| ▸ | MLNR | O43193 | 1/20 | 0.76 |
| ▸ | KDM1A | O60341 | 1/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.76 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.76 |
| ▸ | INSR | P06213 | 1/20 | 0.76 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.76 |
| ▸ | HTR1A | P08908 | 1/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.76 |
| ▸ | DRD2 | P14416 | 1/20 | 0.76 |
| ▸ | NQO2 | P16083 | 1/20 | 0.76 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.76 |
| ▸ | DRD1 | P21728 | 1/20 | 0.76 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.76 |
| ▸ | HTR2A | P28223 | 1/20 | 0.76 |
| ▸ | HTR2C | P28335 | 1/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30116313 | 1.00 | EGFR (1.00) | EGFRKCNH2IGF1RMLNRKDM1A | |
| SCHEMBL14663428 | 1.00 | EGFR (1.00) | EGFRKCNH2IGF1RMLNRKDM1A | |
| SCHEMBL28563010 | 0.94 | EGFR (0.89) | EGFRKCNH2IGF1RMLNRKDM1A | |
| SCHEMBL28571273 | 0.94 | EGFR (0.89) | EGFRKCNH2IGF1RMLNRKDM1A | |
| SCHEMBL28467427 | 0.94 | EGFR (0.88) | EGFRKCNH2IGF1RMLNRKDM1A | |
| SCHEMBL28942100 | 0.94 | EGFR (0.88) | EGFRKCNH2IGF1RMLNRKDM1A | |
| SCHEMBL19540788 | 0.93 | EGFR (0.86) | EGFRKCNH2IGF1RMLNRKDM1A | |
| SCHEMBL22753296 | 0.92 | EGFR (0.86) | EGFRKCNH2IGF1RMLNRKDM1A | |
| SCHEMBL17683246 | 0.91 | EGFR (0.84) | EGFRKCNH2IGF1RMLNRKDM1A | |
| SCHEMBL17683064 | 0.91 | EGFR (0.84) | EGFRKCNH2IGF1RMLNRKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| CN-119979308-A | Microfluidic system and method capable of detecting tumor drug concentration and tumor gene mutation | 上海交通大学医学院附属瑞金医院 | 2025-05-13 | — | — | CN | claimed |
| WO-2025075711-A1 | METHODS AND MATERIALS FOR TREATING HYPEROXALEMIA AND/OR HYPEROXALURIA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-04-10 | — | — | WO | claimed |
| US-20240398943-A1 | METHODS OF TREATING CANCER AND THE PHARMACEUTICAL COMPOSITIONS THEREOF | SYSTIMMUNE, INC. | 2024-12-05 | — | — | US | claimed |
| US-20240384350-A1 | METHODS OF TREATING CANCER WITH KINASE INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-11-21 | — | — | US | claimed |
| EP-4408464-A1 | METHODS OF TREATING CANCER AND THE PHARMACEUTICAL COMPOSITIONS THEREOF | Systimmune, Inc. (US) | 2024-08-07 | — | — | EP | claimed |
| CN-118302192-A | Method for treating cancer and pharmaceutical composition thereof | 西雅图免疫公司 | 2024-07-05 | — | — | CN | claimed |
| CN-118141921-A | Use of CAMK2 inhibitors for the preparation of a medicament for reducing resistance to EGFR-driven cancers | 四川大学 | 2024-06-07 | — | — | CN | claimed |
| EP-4054579-A1 | METHODS FOR THE TREATMENT OF CANCERS THAT HAVE ACQUIRED RESISTANCE TO KINASE INHIBITORS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-09-14 | — | — | EP | claimed |
| WO-2022165214-A1 | METHODS OF TREATING CANCER WITH KINASE INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-08-04 | — | — | WO | claimed |
| CN-114761006-A | Methods of treating cancer resistant to kinase inhibitors | INSERM(法国国家健康医学研究院) | 2022-07-15 | — | — | CN | claimed |
| US-20220218682-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-07-14 | — | — | US | claimed |
| US-20220211706-A1 | Methods and Compositions for Treating Cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-07-07 | — | — | US | claimed |
| US-20220143049-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | VALERIO THERAPEUTICS (FR) | 2022-05-12 | — | — | US | claimed |
| CN-114364798-A | Combination of Dbait molecules with kinase inhibitors for the treatment of cancer | 欧恩科斯欧公司 | 2022-04-15 | — | — | CN | claimed |
| US-11285154-B2 | Methods and compositions for treating cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-03-29 | — | — | US | claimed |
| EP-3965896-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | The United States Government as Represented by the Department of Veterans Affairs (US) | 2022-03-16 | — | — | EP | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240384350-A1 | METHODS OF TREATING CANCER WITH KINASE INHIBITORS | EGFR, BRCA1, ERBB2 | EGFR 1/4885KCNH2 4478/4885IGF1R 711/4885 |
| US-20220143049-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | MAP3K20, MAP3K10, DCK | EGFR 565/4885KCNH2 3818/4885IGF1R 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.